FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients

American Journal of Otolaryngology - Head and Neck Medicine and Surgery

Volumn 35, Issue 6, 2014, Pages 689-694

  Ryan, Marisa ^a   Crow, Jennifer ^a   Kahmke, Russel ^a   Fisher, Samuel R ^a   Su, Zuowei ^a   Lee, Walter T ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; IMMUNOREACTIVITY; MALE; MALIGNANT LENTIGO; MELANOMA; PREVALENCE; RETROSPECTIVE STUDY; SCORING SYSTEM; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SPINDLE CELL;

EID: 84910668692     PISSN: 01960709     EISSN: 1532818X     Source Type: Journal    
DOI: 10.1016/j.amjoto.2014.08.009     Document Type: Article

References (33)

1. A. Jemal, R. Siegel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. A.M. Lachiewicz, M. Berwick, and C.L. Wiggins Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program Arch Dermatol 144 2008 515 521
3. M.J. White, and H.C. Polk Jr. Therapy of primary cutaneous melanoma Med Clin North Am 70 1986 71 87
4. P.A. Gimotty, and D. Guerry Prognostication in thin cutaneous melanomas Arch Pathol Lab Med 134 2010 1758 1763
5. D.L. Larson, and J.D. Larson Head and neck melanoma Clin Plast Surg 37 2010 73 77
6. S.R. Fisher Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998 Laryngoscope 112 2002 99 110
7. S.P. Davison, M.S. Clifton, and L. Kauffman Sentinel node biopsy for the detection of head and neck melanoma: a review Ann Plast Surg 47 2001 206 211
8. D.E. Elder, P.A. Gimotty, and D. Guerry Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features Dermatol Ther 18 2005 369 385
9. C.M. Balch, S.J. Soong, and J.E. Gershenwald Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system J Clin Oncol 19 2001 3622 3634
10. J.E. Gershenwald, W. Thompson, and P.F. Mansfield Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients J Clin Oncol 17 1999 976 983
11. N. de Rosa, G.H. Lyman, and D. Silbermins Sentinel node biopsy for head and neck melanoma: a systematic review Otolaryngol Head Neck Surg 145 2011 375 382
12. C.M. Balch, S. Soong, and M.I. Ross Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial Ann Surg Oncol 7 2000 87 97
13. W.J. Kane, P. Yugueros, and R.P. Clay Treatment outcome for 424 primary cases of clinical I cutaneous malignant melanoma of the head and neck Head Neck 19 1997 457 465
14. W. Chen, X. Liang, and A.J. Peterson The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation J Immunol 181 2008 5396 5404
15. M. Beyer, and J.L. Schultze Regulatory T cells in cancer Blood 108 2006 804 811
16. D.A. Wainwright, M. Dey, and A. Chang Targeting Tregs in malignant brain cancer: overcoming IDO Front Immunol 4 2013 116
17. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
18. J. Guo, J. Zhu, and X. Sheng Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma Int J Cancer 120 2007 2418 2425
19. B. Weide, S. Pascolo, and B. Scheel Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients J Immunother 32 2009 498 507
20. A. Poljak, R. Grant, and C.J. Austin Inhibition of indoleamine 2,3 dioxygenase activity by H2O2 Arch Biochem Biophys 450 2006 9 19
21. H. Fujigaki, K. Saito, and F. Lin Nitration and inactivation of IDO by peroxynitrite J Immunol 176 2006 372 379
22. G.D. Basu, T.L. Tinder, and J.M. Bradley Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO J Immunol 177 2006 2391 2402
23. R.B. Holmgaard, D. Zamarin, and D.H. Munn Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 J Exp Med 210 2013 1389 1402
24. A.C. Knol, J.M. Nguyen, and G. Quereux Prognostic value of tumor-infiltrating Foxp3 + T-cell subpopulations in metastatic melanoma Exp Dermatol 20 2011 430 434
25. A. Ladanyi, A. Mohos, and B. Somlai FOXP3 + cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma Pathol Oncol Res 16 2010 303 309
26. A. Mohos, T. Sebestyen, and G. Liszkay Immune cell profile of sentinel lymph nodes in patients with malignant melanoma - FOXP3 + cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome J Transl Med 11 2013 43
27. A.S. Mansfield, P.S. Heikkila, and A.T. Vaara Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer BMC Cancer 9 2009 231
28. J.H. Lee, Y. Chen, and J.L. Chan Molecular analysis of melanoma-induced sentinel lymph node immune dysfunction Cancer Immunol Immunother 60 2011 685 692
29. J.R. Brody, C.L. Costantino, and A.C. Berger Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival Cell Cycle 8 2009 1930 1934
30. D. Mougiakakos, C.C. Johansson, and E. Trocme Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma Cancer 116 2010 2224 2233
31. R. Speeckaert, K. Vermaelen, and N. van Geel Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients Eur J Cancer 48 2012 2004 2011
32. K. Laimer, B. Troester, and F. Kloss Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas Oral Oncol 47 2011 352 357
33. M.D. Sharma, D.Y. Hou, and Y. Liu Indoleamine 2,3-dioxygenase controls conversion of Foxp3 + Tregs to TH17-like cells in tumor-draining lymph nodes Blood 113 2009 6102 6111